December 14, 2025

How can we optimise decision-making for complex/high-risk kidney stone patients? A discussion between Prof. Somani, Dr. Breeggemann and Dr. Bryant

27 minutes

In this episode "How can we optimise decision-making for complex/high-risk kidney stone patients?" Prof. Bhaskar Somani (GB) is joined by Dr. Matthew Breeggemann (US) and Dr. Timothy Bryant (GB) to explore the practical value and challenges of multidisciplinary collaboration in stone disease management.

The speakers reflect on how shared decision-making within a structured stone MDT can support better outcomes for complex or high-risk recurrent kidney stone patients. Using a real-life case example, they walk through the patient journey, examining how early specialist input and coordinated care can impact diagnosis, treatment planning and follow-up.

They discuss the current gaps in guideline implementation, particularly where patient complexity demands input beyond standard urological care. The role of nephrology, radiology and dietetics in MDT decision-making is highlighted, emphasising the need for clear communication and flexible protocols. The speakers also address challenges, such as delays in imaging or conflicting clinical opinions and how MDT formats can help resolve these through consensus-building.

The importance of tailoring care to individual risk profiles is underscored, along with suggestions for integrating MDT principles into both large and smaller healthcare systems. The episode concludes with practical recommendations for centres looking to establish or improve a stone MDT. This conversation provides valuable insight for clinicians involved in managing stone disease and those working toward more coordinated care models.

You can also listen to the previously released episode:

Identifying high-risk stone formers: How can we improve early diagnosis and referral? A discussion between Prof. Somani, Prof. Ferraro and Prof. Emiliani

Acknowledgment

Medical writing support was provided by Accenture Song Life Sciences with unrestricted funding from Novo Nordisk, with no involvement in the programme or speaker selection.

...more

View all episodes

By European Association of Urology

3.7

33 ratings